LONDON (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.
Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch13
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft7
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16